Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Ed Lavelle

Prof/ Course Co-Ordinator (Biochemistry)


I am an Immunologist and have been Head of the School of Biochemistry and Immunology since 2017. I have engaged at teaching at many levels in Universities in Ireland and the U.K. In particular, since October 2004 I have worked as a lecturer, senior lecturer and Professor in Immunology in the School of Biochemistry and Immunology at Trinity College Dublin. In addition to delivering lectures and tutorials to junior and senior sophister students, I have also lectured to students enrolled on the MSc courses in Molecular Medicine, Immunology and Translational Oncology. I was also previously engaged in lecturing at TCD and at the University of Nottingham (England). I have supervised student projects from diploma to Masters degree level and have supervised 17 PhD students to completion. I have been President of the Irish Society for Immunology since 2012, organised a number of National and International conferences, chaired sessions on Immunology and vaccines for a number of national and international conferences and acted as a peer reviewer for leading Immunology journals and for funding bodies in both the EU and the USA. Since acquiring my PhD in 1994, my research has been principally in the fields of Immunology and vaccine adjuvant development. The projects I have worked on have included the piscine mucosal immune system, the use of biodegradable micro and nanoparticles as vaccine adjuvants and the evaluation of plant lectins as bioadhesives, immunogens and immunomodulators. During this time I acquired broad expertise that is applicable to the range of projects I am now engaged in and will pursue in the future. In recent years my principal research interest has been the elucidation of the mechanism of action of adjuvants and immunomodulators. In particular I have focused on on particulate vaccine adjuvants including biodegradable microparticles, alum and the cationic polysaccharide chitosan. This work includes basic research into the mechanism by which these systems activate the immune system and more applied work on the optimisation of these adjuvants for use in injectable and mucosal vaccines. The fundamental adjuvant research includes studies into the cell signalling pathways induced by these molecules which will facilitate a better understanding of their mode(s) of action. In addition, over the past number of years my team have worked closely with our collaborators within AMBER to address the potential of novel biomaterials to drive beneficial immune responses underpinning tissue regeneration. Across all of our activities we depend on building and sustaining close collaborations with national and international academic and industrial collaborators.
  ADENYLYL-CYCLASE ACTIVITY   ADJUVANTS   cAMP   Cell Death   CREB   IL-10   Immune System   Immunity   Immunology, Immunotherapy   Immunophysiology   Inflammation   LECTIN-BINDING   LECTINS   Life Sciences   Nanotechnology   NF-kappaB   Signal Transduction   Signal Transduction (Sensory/Cellular)   SIGNAL-TRANSDUCTION   SIGNAL-TRANSDUCTION PATHWAYS   Toll-Like Receptors   VACCINE   VACCINE EFFICACY   Vaccines
 Tailored design of nanoparticulate adjuvants to enhance vaccine induced cellular immunity
 Adjuvants targeting the NLRP3 inflammasome and STING for improved cancer immunotherapy.
 Potential of oral cyclosporine to treat extra-intestinal diseases
 Sugar coating immunity for enhancement of biomaterials.
 Irish Society for Immunology meeting 2018.

Page 1 of 9
Details Date
Chair of the Steering committee for the Centre for Global Vaccine Research, University of Liverpool, U.K. (2017-2020).
Main organiser of 9 Immunology meetings including the Irish Society for Immunology meetings (2013-2020; average attendance 160-200 participants) and the European Mucosal Immunology Group (EMIG) 2012 meeting (300 participants), held in Dublin.
Member of the advisory board for the EU funded ITN, PHA-ST-TRAIN-VAC between the University of Strathclyde and GSK Vaccines (2017-2019).
National representative and member of the core group of the COST Action ENOVA (European Network of Vaccine adjuvants) 2018-2022.
Member of the Scientific Advisory Panel for 13 international conferences since 2006.
Won the bid to host the 2024 European Congress of Immunology in Dublin in 2024. I will lead the committee in planning for this meeting for the coming 5 years.
Member of the Editorial Board of Biochemical Pharmacology and Frontiers in Immunology
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Medium Medium Medium
Irish Medium Medium Medium
Spanish Basic Basic Basic
Details Date From Date To
Irish Society for Immunology (President) 2005 (member) 2020
Committee member of the Vaccine committee for the International Union of Immunological Societies (IUIS). 2018 2020
European Federation of Immunology Societies 2005 2019
International Society of Vaccines 2019 2020
Society for Mucosal Immunology 2006 2020
The American Association of Immunologists 2018 2020
European Adjuvant Advisory Group 2007 2008
Schijns, V., Fernández-Tejada, A., Barjaktarović, Z., Bouzalas, I., Brimnes, J., Chernysh, S., Gizurarson, S., Gursel, I., Jakopin, Z., Lawrenz, M., Nativi, C., Paul, S., Pedersen, G.K., Rosano, C., Ruiz-de-Angulo, A., Slütter, B., Thakur, A., Christensen, D. and Lavelle, E.C., Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. , Immunological Reviews , 2020, Journal Article, PUBLISHED
McEntee, C.P., Moran, H.B.T., Muñoz-Wolf, N., Liddicoat, A.M., Carroll, E.C., Erbo-Wern, J., Coulter, I.S., Andersen, P., Follmann, F. and Lavelle, E.C. (2020). , Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming. , Vaccine, 38, (3), 2020, p635 - 643, Notes: [doi: 10.1016/j.vaccine.2019.10.047.], Journal Article, PUBLISHED  DOI
Lemoine C, Thakur A, Kraji"nik D, Guyon R, Longet S, Razim A, Górska S, Panteli" I, Ili" T, Nikoli" I, Lavelle EC, Gamian A, Savi" S, Milicic A., Technological Approaches for Improving Vaccination Compliance and Coverage., Vaccines, 8, (2), 2020, pE304-, Notes: [doi: 10.3390/vaccines8020304.], Journal Article, PUBLISHED  DOI
Z. Zas³ona , E. Flis, M.M. Wilk, R.G. Carroll, E.M. Palsson-McDermott, M.M. Hughes, C. Diskin, K. Banahan, D.G. Ryan, A. Hooftman, A. Misiak, J. Kearney, G. Lochnit, W. Bertrams, T. Greulich, B. Schmeck, O.J. McElvaney, K.H.G. Mills, E.C. Lavelle, M. Wygrecka, E.M. Creagh & L.A.J. O'Neill , Caspase-11 promotes allergic airway inflammation, Nature Communications, 2020, Notes: [10.1038/s41467-020-14945-2], Journal Article, PUBLISHED  TARA - Full Text  URL
Hackett, E.E., Charles-Messance, H., O'Leary, S.M., Gleeson, L.E., Muñoz-Wolf, N., Case, S., Wedderburn, A., Johnston, D.G.W., Williams, M.A., Smyth, A., Ouimet, M., Moore, K.J., Lavelle, E.C., Corr, S.C., Gordon, S.V., Keane, J., Sheedy, F.J., Mycobacterium tuberculosis Limits Host Glycolysis and IL-1ß by Restriction of PFK-M via MicroRNA-21, Cell Reports, 30, (1), 2020, p124-136.e4 , Journal Article, PUBLISHED
Shears RK, Jacques LC, Naylor G, Miyashita L, Khandaker S, Lebre F, Lavelle EC, Grigg J, French N, Neill DR, Kadioglu A., Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease., The Journal of allergy and clinical immunology, 145, (4), 2020, p1272-1284.e6 , Journal Article, PUBLISHED  DOI
Lebre F, Boland JB, Gouveia P, Gorman AL, Lundahl MLE, I Lynch R, O'Brien FJ, Coleman J, Lavelle EC., Pristine graphene induces innate immune training., Nanoscale, 12, (20), 2020, p11192-11200 , Journal Article, PUBLISHED  DOI
Schijns V, Lavelle EC., Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity., European journal of immunology, 2020, Journal Article, PUBLISHED  DOI
O'Grady, K., Hearnden, C.C.H., Bento, D., Oleszycka, E., Andersen, P., Muñoz-Wolf, N. and Lavelle, E.C. , IL-33 is a negative regulator of vaccine-induced antigen-specific cellular immunity, The Journal of Immunology, 2019, Journal Article, IN_PRESS
Nazmi, A., Field, R.H., Griffin, E.W., Haugh, O., Hennessy, E., Cox, D., Reis, R., Tortorelli, L., Murray, C.L., Lopez-Rodriguez, A.B., Lavelle, E.C., Dunne, A. and Cunningham,C. , Chronic neurodegeneration induces Type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression, Glia, 67, 2019, p1254 - 1276 , Journal Article, PUBLISHED  TARA - Full Text  DOI
  

Page 1 of 15
Shears, R.K., Jacques, L.C., Naylor, G., Miyashita, L., Khandaker, S., Lebre, F. and Lavelle, E.C., Grigg, J., French, N., Neill, D.R. and Kadioglu, A. , (2020). Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease. , J Allergy Clin Immunol., 145, (4), 2020, p1272 - 1284, Notes: [10.1016/j.jaci.2019.11.039. ], Journal Article, PUBLISHED

  

Award Date
Fellow of Trinity College Dublin 2012
Made an ambassador of the Dublin Convention Centre 2018
Elected President of the Irish Society for Immunology 2013
Prof Ed Lavelle is an internationally recognised vaccine researcher with a record of publishing high impact papers, attracting competitive research funding, generating and protecting intellectual property, engaging industrial partners and the public, organising conferences and adopting advisory roles in the vaccine field. My research is in the area of vaccination, principally focused on how vaccine adjuvants enhance protective immune responses. Adjuvants are essential components of vaccines that can profoundly affect the magnitude and type of adaptive immunity induced. My group concentrates on particulate adjuvants and over recent years has made key discoveries that enhance our understanding of how the physicochemical properties of adjuvants influence the induction of innate and adaptive immunity. We have provided key insights into how adjuvants engage innate cellular sensing pathways, particularly DNA sensing pathways and inflammasomes, pursuing the specific roles of interferons and cytokines of the IL-1 family in adjuvanticity. In addition, we have made advances in the development of novel injectable and mucosal vaccines, demonstrating that the optimal type of adjuvant depends the antigen and mode of vaccination. We have worked on developing an effective oral delivery system that has significant potential for vaccines against ETEC, cholera and Helicobacter pylori. The expertise we have developed in assessing particulate adjuvant regulation of immune responses has relevance in the field of biomaterial interaction with the immune system. As a result, we now have a substantial research programme in this area as part of the AMBER centre. Being a CRANN PI and an AMBER funded investigator has led to close connections with colleagues in Bioengineering, Chemistry and Physics and this cross-disciplinary dimension will be a key driver of my future research. I believe that this also underscores and supports the principal focus of the laboratory in dissecting how particulate materials can regulate immune responses and how fundamental understanding of the underlying processes can help us to rationally design novel vaccine adjuvant systems but also enhanced biomaterials. My work has been transformational over the past 16 years in establishing that nonmicrobial particulates can be designed to activate specific innate sensing and signalling pathways and that this can be harnessed to induce and direct adaptive immune responses. This has led to publications in the leading journals in the field, a number of these since my last promotion in 2015. The impact of my work can be seen in invitations to speak at the leading meetings in the field (103 invited conference talks and seminars since 2004), to serve on scientific advisory boards for conferences (15), to serve as chair on the advisory board of a vaccine centre, to act as a consultant for leading human (Merck) and veterinary (HIPRA) vaccine companies, to write reviews, commentaries and editorials and to serve as a panel member for prestigious grant agencies (e.g. Gates Foundation, German Centres of Excellence Programme). I am recognised as a leader in vaccine adjuvant research and given the growing prominence of this field I believe that my influence will grow, generating many new research opportunities over the coming years.